REVERSAL OF METHYLMERCAPTOPURINE RIBONUCLEOSIDE CYTOTOXICITY BY PURINE RIBONUCLEOSIDES AND ADENINE

被引:20
作者
STET, EH [1 ]
DEABREU, RA [1 ]
BOKKERINK, JPM [1 ]
LAMBOOY, LHJ [1 ]
VOGELSMENTINK, TM [1 ]
KEIZERGARRITSEN, JJ [1 ]
TRIJBELS, FJM [1 ]
机构
[1] UNIV NIJMEGEN ST RADBOUD HOSP, CTR PEDIAT ONCOL SE NETHERLANDS, DEPT PEDIAT, 6500 HB NIJMEGEN, NETHERLANDS
关键词
D O I
10.1016/0006-2952(94)00387-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
6-Methylmercaptopurine ribonucleoside-5'-phosphate (MeSPuRMP), the sole metabolite of 6-methylmercaptopurine ribonucleoside (MeSPuRib), is a strong inhibitor of purine de novo synthesis, inducing depletion of intracellular purine nucleotides and subsequent cell death in several tumor cell lines. In this study prevention of MeSPuRib cytotoxicity by compounds of the purine salvage pathway was studied in Molt F4 human malignant T-lymphoblasts. Adenosine, adenine and inosine were able to prevent depletion of the adenine nucleotide pool when used in combination with 0.5 mu M MeSPuRib, but had virtually no effect on depletion of guanine nucleotides. Nevertheless, these three purine compounds were able to reduce the cytotoxic effects induced by MeSPuRib. Addition of guanosine to cells treated with 0.5 mu M MeSPuRib normalized the guanine nucleotide pool, but adenine nucleotides remained depleted. Under these conditions, inhibition of cell growth was significantly decreased. With the combination of guanosine and 10 mu M MeSPuRib, cytotoxicity was increased compared to 10 mu M MeSPuRib alone, associated with a depletion of adenine nucleotides to 9% of untreated cells. Since cell growth and cell viability of Molt F4 cells are less inhibited by MeSPuRib under conditions where adenine nucleotide depletion is prevented by purine compounds (and where the other nucleotides are depleted) we conclude that depletion of adenine nucleotides is an important factor in MeSPuRib cytotoxicity.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 31 条
[1]  
BALZARINI J, 1991, J BIOL CHEM, V266, P21509
[2]   REVERSAL OF GROWTH INHIBITORY EFFECTS OF 6-METHYLTHIOPURINE RIBONUCLEOSIDE [J].
BENNETT, LL ;
ADAMSON, DJ .
BIOCHEMICAL PHARMACOLOGY, 1970, 19 (06) :2172-&
[3]   ACTIVITY AND MECHANISM OF ACTION OF 6-METHYLTHIOPURINE RIBONUCLEOSIDE IN CANCER CELLS RESISTANT TO 6-MERCAPTOPURINE [J].
BENNETT, LL ;
BROCKMAN, RW ;
SCHNEBLI, HP ;
CHUMLEY, S ;
DIXON, GJ ;
SCHABEL, FM ;
DULMADGE, EA ;
SKIPPER, HE ;
MONTGOMERY, JA ;
THOMAS, HJ .
NATURE, 1965, 205 (4978) :1276-+
[4]   EFFECTS OF METHOTREXATE ON PURINE AND PYRIMIDINE METABOLISM AND CELL-KINETIC PARAMETERS IN HUMAN-MALIGNANT LYMPHOBLASTS OF DIFFERENT LINEAGES [J].
BOKKERINK, JPM ;
DEABREU, RA ;
BAKKER, MAH ;
HULSCHER, TW ;
VANBAAL, JM ;
SCHRETLEN, EDAM ;
DEBRUIJN, CHMM .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (12) :2329-2338
[5]   6-MERCAPTOPURINE - CYTOTOXICITY AND BIOCHEMICAL PHARMACOLOGY IN HUMAN-MALIGNANT T-LYMPHOBLASTS [J].
BOKKERINK, JPM ;
STET, EH ;
DEABREU, RA ;
DAMEN, FJM ;
HULSCHER, TW ;
BAKKER, MAH ;
VANBAAL, JA .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (07) :1455-1463
[6]   ENZYMIC FORMATION OF 6-(METHYLMERCAPTO)PURINE RIBONUCLEOSIDE 5'-PHOSPHATE [J].
CALDWELL, IC ;
HENDERSON, JF ;
PATERSON, AR .
CANADIAN JOURNAL OF BIOCHEMISTRY, 1966, 44 (02) :229-+
[7]  
COHEN MB, 1983, CANCER RES, V43, P1587
[8]  
DAYTON JS, 1992, MOL PHARMACOL, V41, P671
[9]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR IDENTIFICATION AND QUANTITATION OF NUCLEOTIDES IN LYMPHOCYTES AND MALIGNANT LYMPHOBLASTS [J].
DEABREU, RA ;
VANBAAL, JM ;
BAKKEREN, JAJM ;
DEBRUYN, CHMM ;
SCHRETLEN, EDAM .
JOURNAL OF CHROMATOGRAPHY, 1982, 227 (01) :45-52
[10]  
GRINDEY GB, 1976, CANCER RES, V36, P379